B. Riley Issues Optimistic Estimate for ETON Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Investment analysts at B. Riley raised their Q3 2025 EPS estimates for shares of Eton Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 19th. B. Riley analyst M. El-Saadi now forecasts that the company will earn $0.14 per share for the quarter, up from their prior forecast of $0.04. B. Riley currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals’ Q4 2025 earnings at $0.25 EPS, FY2025 earnings at $0.44 EPS, FY2026 earnings at $1.08 EPS, FY2027 earnings at $1.45 EPS, FY2028 earnings at $1.66 EPS and FY2029 earnings at $1.82 EPS.

A number of other research firms also recently commented on ETON. HC Wainwright reiterated a “buy” rating and set a $33.00 target price on shares of Eton Pharmaceuticals in a research report on Wednesday. Craig Hallum increased their price objective on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday.

Eton Pharmaceuticals Price Performance

ETON opened at $14.78 on Friday. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $18.41. The stock has a market cap of $385.03 million, a P/E ratio of -67.18 and a beta of 1.37. The stock’s 50 day simple moving average is $15.56 and its 200 day simple moving average is $11.47.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The company had revenue of $11.65 million for the quarter, compared to analyst estimates of $10.53 million.

Hedge Funds Weigh In On Eton Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Connor Clark & Lunn Investment Management Ltd. increased its position in Eton Pharmaceuticals by 86.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after purchasing an additional 30,167 shares in the last quarter. Wasatch Advisors LP purchased a new stake in shares of Eton Pharmaceuticals during the third quarter worth about $1,431,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Eton Pharmaceuticals in the third quarter valued at approximately $54,000. Parkman Healthcare Partners LLC lifted its stake in shares of Eton Pharmaceuticals by 2.8% during the third quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock valued at $1,561,000 after buying an additional 7,029 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Eton Pharmaceuticals during the third quarter worth approximately $90,000. 27.86% of the stock is owned by institutional investors and hedge funds.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.